Results 71 to 80 of about 392,253 (296)

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

BMC Cancer, 2020
Background The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR)-positive, human epidermal growth
Guangfu Hu, Guangxia Hu, Chengjiao Zhang, Xiaoyan Lin, Ming Shan, Yanmin Yu, Yongwei Lu, Ruijie Niu, Hui Ye, Cheng Wang, Cheng Xu   +10 more
doaj   +1 more source

Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma [PDF]

, 2016
BACKGROUND: This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III).
ANTONELLI, MANILA, Balter, Rita, Barra, Salvina, Bertin, Daniele, Bertolini, Patrizia, Biassoni, Veronica, Boschetti, Luna, Buccoliero, Annamaria, BUTTARELLI, Francesca Romana, Calareso, Giuseppina, Cama, Armando, Cinalli, Giuseppe, Diletto, Barbara, Ferroli, Paolo, Gandola, Lorenza, Garrè, Maria Luisa, Genitori, Lorenzo, GIANGASPERO, FELICE, Giombelli, Ermanno, Giussani, Carlo, La Spina, Milena, Marras, Carlo Efisio, Mascarin, Maurizio, Massimino, Maura, MASTRONUZZI, ANGELA, Miceli, Rosalba, Modena, Piergiorgio, Mussano, Anna, Pecori, Emilia, Peretta, Paola, Pollo, Bianca, Quaglietta, Lucia, Sardi, Iacopo, Scarzello, Giovanni, Schiavello, Elisabetta, Scoccianti, Silvia, Valentini, Laura, Viscardi, Elisabetta   +37 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Fetal Brain Tumor Harboring a Unique ROCK1::BRAF Fusion

Pediatric Blood &Cancer, EarlyView.
Marllon Cindra Sant'Ana, Mariana Maschietto, Daniela Paz Leal, Ricardo de Santos de Oliveira, Mayara Ferreira Euzébio, Antonio Carlos dos Santos, Luciano Neder, Carlos Alberto Scrideli, Elvis Terci Valera   +8 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. [PDF]

, 2015
BACKGROUND: The relationship between chemotherapy-related toxicities and prognosis is unclear. Previous studies have examined the association of myelosuppression parameters or neuropathy with survival and reported conflicting results.

core   +2 more sources

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]

, 2011
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van, Joore, M.A., Retèl, Valesca P., Rutgers, E.J.Th.   +3 more
core   +1 more source